Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled dose-finding study of YY-162 in pediatric ADHD
KCT0000332Phase 3Recruiting
- Sponsor
- Gangwon Leading Industry Office
- Start
- Dec 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing YY-162 dose-finding arm(s) with Placebo arm (2 arms). Started Dec 2011; status: recruiting.
02
Drugs
YY-162
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on KCT0000332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000332.